Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desvenlafaxine versus venlafaxine in major depressive disorder
ChiCTR2500097633Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Mianyang
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of desvenlafaxine and venlafaxine in major depressive disorder (MDD) (2 arms), sponsored by The Third Hospital of Mianyang. Primary endpoints: Incidence of adverse events/adverse reactions and Change in HAMD score from baseline. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
desvenlafaxinevenlafaxine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2500097633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097633.